Detalhe da pesquisa
1.
Sensitivity of Pharmacokinetics to Differences in the Particle Size Distribution for Formulations of Locally Acting Mometasone Furoate Suspension-Based Nasal Sprays.
Mol Pharm
; 20(11): 5690-5700, 2023 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37773975
2.
Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers.
Pharm Res
; 34(12): 2541-2556, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28799097
3.
Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects.
Clin Pharmacokinet
; 61(5): 687-695, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34961905
4.
Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel.
Clin Transl Sci
; 15(8): 1906-1915, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35583936
5.
Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis.
Clin Drug Investig
; 41(8): 711-721, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34331678
6.
Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor.
Thromb Haemost
; 121(6): 755-766, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33412611
7.
Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
AAPS J
; 23(3): 48, 2021 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33768368
8.
Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists.
Clin Pharmacokinet
; 59(5): 545-566, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32056160
9.
Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel.
Clin Transl Sci
; 13(5): 886-890, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32166864
10.
Correction to: Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
AAPS J
; 24(1): 1, 2021 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34811595